Update for receipt of copy of order related to scheme of Amalgamation of Dhanuka Laboratories limited and Orchid Pharma limited
M&A
● No Immediate Change
LOW RISK
📅 Filed on BSE: 12 Jun 2026, 12:57 PM IST · BSE ID: bffdd4dd-eb83-451b-80a1-484b9c0e07a7
View Original BSE Filing (PDF)
💡
In Simple Terms
Orchid Pharma received the official court order for its merger with Dhanuka Laboratories, with an effective date of April 01, 2024.
🤖 AI Summary
- Orchid Pharma received the National Company Law Tribunal (NCLT) order copy dated June 05, 2026.
- The order approves the Scheme of Amalgamation between Dhanuka Laboratories Limited and Orchid Pharma Limited.
- The Appointed Date for the Scheme of Amalgamation is April 01, 2024.
- The amalgamation will be effective upon completion of steps specified in the Scheme.
- Orchid Pharma will provide further updates upon the Scheme's effectiveness.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Potential Sales Turnover (Combined)
Rs. 1400-1500 crores
Potential EBITDA (Combined)
Rs. 200 to Rs. 250 crores
🏢 How This Affects the Company
The amalgamation aims to create a larger combined entity with a potential sales turnover of up to Rs. 1400-1500 crores and EBITDA of Rs.200 to Rs. 250 crores.
The combined entity expects to achieve a stronger balance sheet by pooling financial resources and eliminating inter-company conflicts.
The merger seeks to streamline group structure, reduce legal entities, and ensure focused management through consolidated operations.
The amalgamation, aligning with a May 16, 2019 resolution plan, aims to integrate operations, potentially reducing operational risks associated with separate entities in similar businesses.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders of both Orchid Pharma Limited and Dhanuka Laboratories Limited will be affected by the Scheme of Amalgamation once it becomes effective, as their holdings will be governed by the Scheme's terms.
🔍
Management Signal
Management is progressing with the previously announced amalgamation, indicating a commitment to the stated strategic objectives of the merger.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Update from Orchid Pharma on the Scheme of Amalgamation becoming effective.
Disclosure of specific steps completed for the Scheme to be effective.
Release of combined financial statements post-amalgamation effectiveness.
LOW RISK
The NCLT approval process for the merger is now complete, reducing regulatory uncertainty.
💡 Investor Takeaway
Orchid Pharma received the NCLT order copy on June 12, 2026, sanctioning the amalgamation with Dhanuka Laboratories. The Appointed Date of the Scheme is April 01, 2024, with effectiveness pending completion of specified steps.
⚖️ Strengths & Concerns
✅ Positives
- The amalgamation aims to achieve a combined sales turnover of up to Rs. 1400-1500 crores, enhancing market presence.
- The merger intends to result in an EBITDA of Rs.200 to Rs. 250 crores, indicating potential for improved profitability.
⚠️ Concerns
- The Scheme's effectiveness depends on completing additional unspecified steps, indicating further procedural requirements.
- No immediate financial changes are detailed in the current filing, as the Scheme is not yet effective.
📅 Company Track Record
Orchid Pharma previously intimated the NCLT sanction for its amalgamation with Dhanuka Laboratories on June 05, 2026. This followed an update on March 18, 2026, confirming the merger scheme without disclosing specific terms or timelines.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the status of Orchid Pharma's amalgamation with Dhanuka Laboratories?
Orchid Pharma has received the copy of the order pronounced by the Hon’ble National Company Law Tribunal (NCLT) on June 05, 2026, allowing the merger petition for the Scheme of Amalgamation.
What is the Appointed Date for the amalgamation scheme?
The Appointed Date of the Scheme of Amalgamation between Dhanuka Laboratories Limited and Orchid Pharma Limited is April 01, 2024.
When will the amalgamation become effective?
The amalgamation will become effective upon completion of the steps as laid out in the Scheme, following the NCLT order.
What is the potential sales turnover targeted after the amalgamation?
The resolution plan projects a potential sales turnover of up to Rs. 1400-1500 crores for the combined entity after the amalgamation.
What is the expected EBITDA after the merger?
The resolution plan for the amalgamation projects an EBITDA of Rs.200 to Rs. 250 crores for the combined entity.
Questions based on this BSE filing only. For information purposes.